GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (XTER:EVT) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Evotec SE (XTER:EVT) Future 3-5Y EPS without NRI Growth Rate : N/A (As of May. 05, 2025)


View and export this data going back to 1999. Start your Free Trial

What is Evotec SE Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Evotec SE's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Evotec SE's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evotec SE's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Evotec SE's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Evotec SE  (XTER:EVT) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Evotec SE Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Evotec SE's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (XTER:EVT) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
XTER:B8FK ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA SHSE:688506 BOM:500087 TSE:4507 SZSE:000538 UTHR NSE:TORNTPHARM BOM:543904 BOM:500124 BOM:500257
Traded in Other Exchanges
EVO:USA 1EVT:Italy EVTd:UK 0IRF:UK EVT:Bulgaria EVT:Austria
Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Website
https://www.evotec.com
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Executives
Dr. Christian Wojczewski Board of Directors
Aurélie Dalbiez Board of Directors
Prof. Dr. Iris Löw-friedrich Supervisory Board
Dr. Craig Johnstone Board of Directors
Dr. Cord Dohrmann Board of Directors
Dr. Werner Lanthaler Board of Directors